Tissue Plasminogen Activator Use in Children: Bleeding Complications and Thrombus Resolution.

[1]  N. Ceviz,et al.  Clinical experience with recombinant tissue plasminogen activator in the management of intracardiac and arterial thrombosis in children , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[2]  M. Lungren,et al.  Endovascular venous thrombolysis in children younger than 24 months. , 2014, Journal of vascular and interventional radiology : JVIR.

[3]  J. L. Todd,et al.  Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. , 2013, Circulation.

[4]  R. Goel,et al.  Antithrombotic therapies: anticoagulation and thrombolysis. , 2013, Pediatric clinics of North America.

[5]  J. Moore,et al.  Low dose tissue plasminogen activator treatment for vascular thrombosis following cardiac catheterization in children: A single center experience , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[6]  B. Baytan,et al.  Thrombolysis With Recombinant Tissue Plasminogen Activator in 7 Children , 2013, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[7]  B. McCrindle,et al.  Thrombotic complications and thromboprophylaxis across all three stages of single ventricle heart palliation. , 2012, The Journal of pediatrics.

[8]  B. Kerlin,et al.  Pediatric venous thromboembolism in the United States: A tertiary care complication of chronic diseases , 2012, Pediatric blood & cancer.

[9]  S. Vesely,et al.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[10]  W. Middlesworth,et al.  The use of recombinant tissue-type plasminogen activator in a newborn with an intracardiac thrombus developed during extracorporeal membrane oxygenation. , 2011, Journal of pediatric surgery.

[11]  J. Stockman.  Dramatic Increase in Venous Thromboembolism in Children's Hospitals in the United States from 2001 to 2007 , 2011 .

[12]  S. Leary,et al.  Low-dose Systemic Thrombolytic Therapy for Deep Vein Thrombosis in Pediatric Patients , 2010, Journal of pediatric hematology/oncology.

[13]  M. Manco‐Johnson,et al.  A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. , 2007, Blood.

[14]  M. Albisetti.  Thrombolytic therapy in children. , 2006, Thrombosis research.

[15]  K. Deeg,et al.  Diagnosis of neonatal aortic thrombosis by colour coded Doppler sonography , 2005, Pediatric Radiology.

[16]  L. Valentino,et al.  Low-Dose Tissue Plasminogen Activator Thrombolysis in Children , 2003, Journal of pediatric hematology/oncology.

[17]  W. Baker.  Thrombolytic therapy: clinical applications. , 2003, Hematology/oncology clinics of North America.

[18]  M. Wang,et al.  Recommendations for tPA Thrombolysis in Children , 2002, Thrombosis and Haemostasis.

[19]  B. McCrindle,et al.  Safety and outcomes of thrombolysis with tissue plasminogen activator for treatment of intravascular thrombosis in children. , 2001, The Journal of pediatrics.

[20]  A. Gurgey,et al.  Outcome of Noncatheter-Related Thrombosis in Children: Influence of Underlying or Coexisting Factors , 2001, Journal of pediatric hematology/oncology.

[21]  P. Monagle,et al.  Antithrombotic therapy in children. , 2001, Chest.

[22]  S. Goldhaber.  Pulmonary Embolism , 1999, Springer Japan.

[23]  R. Faix,et al.  Successful treatment of neonatal arterial thromboses with recombinant tissue plasminogen activator. , 1998, The Journal of pediatrics.

[24]  G. Sebag,et al.  Recombinant tissue-type plasminogen activator therapy of thrombosis in 16 neonates. , 1998, The Journal of pediatrics.

[25]  M. Bernstein,et al.  Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE , 1994 .

[26]  G. Koren,et al.  Tissue plasminogen activator for the treatment of thromboembolism in infants and children. , 1991, The Journal of pediatrics.

[27]  B. Anderson,et al.  Caval Thrombolysis in Neonates Using Low Doses of Recombinant Human Tissue-Type Plasminogen Activator , 1991, Anaesthesia and intensive care.

[28]  M. Gent,et al.  Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. , 1990, Chest.

[29]  Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. , 1989, The New England journal of medicine.